21821-40-9

Usage

Uses

Used in Pharmaceutical Industry:
4-(5-Formyl-2-furyl)benzene-1-sulfonamide is used as a potential active pharmaceutical ingredient for the development of drugs with antibacterial, antiviral, and anti-inflammatory properties. Its unique structure allows it to target specific biological pathways and mechanisms, offering new therapeutic options for various diseases.
Used in Medicinal Chemistry Research:
4-(5-Formyl-2-furyl)benzene-1-sulfonamide is used as a research compound for exploring its potential applications in the treatment of various diseases. Its structure and properties make it a valuable tool for understanding the mechanisms of action and developing new therapeutic strategies.
Used as a Building Block in Synthesis:
4-(5-Formyl-2-furyl)benzene-1-sulfonamide is used as a building block for the synthesis of novel pharmaceutical compounds. Its unique structure can be modified and combined with other chemical entities to create new molecules with potential therapeutic applications.

InChI:InChI=1/C11H9NO4S/c12-17(14,15)10-4-1-8(2-5-10)11-6-3-9(7-13)16-11/h1-7H,(H2,12,14,15)

Upstream product

• 1899-24-7 5-bromo-2-furancarboxaldehyde 
• 613660-87-0 4-sulfamoylphenylboronic acid 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 27329-70-0 5-formylfurane-2-boronic acid 
• 701-34-8 4-bromo-benzenesulfonic acid amide 
• 98-01-1 furfural 
• 35282-78-1 4-(aminosulphonyl)benzenediazonium chloride 

Downstream Products

• 336178-16-6 C₂₂H₁₇N₃O₆S 
• 1619995-17-3 4-{5-[(E)-(naphthalen-2-ylimino)methyl]furan-2-yl}benzenesulfonamide 
• 1619995-06-0 4-[5-(9,9-dimethyl-11-oxo-7,8,9,10,11,12-hexahydrobenzo[a]acridin-12-yl)furan-2-yl]benzenesulfonamide 
• 441718-16-7 methyl 4-(3,5-dioxo-4-((5-(4-sulfamoylphenyl)furan-2-yl)methylene)pyrazolidin-1-yl)benzoate 
• 765938-44-1 3-[5-(4-aminosulfonylphenyl)-2-furyl]acrylic acid 

Relevant academic research and scientific papers

Acrylamide derivative and preparation method and application thereof

The invention belongs to the field of chemical medicines, and particularly relates to an acrylamide derivative. The acrylamide derivative adopts a structural general formula as follows: FORMULA. Someembodiments of the acrylamide derivative confirm that th

Synthesis of 12-hetaryl-9,9-dimethyl-7,8,9,10-tetrahydrobenzo[a]acridin- 11(12H)-ones

Three-component condensation of naphthalen-2-amine with 5-arylfuran(thiophene, N-methylpyrrole)-2-carbaldehyde and 5,5- dimethylcyclohexane-1,3-dione, as well as condensation of N-[(5- arylfuran(thiophen)-2-ylmethylidene]naphthalen-2-amine with 5,5- dimethylcyclohexane-1,3-dione gave the corresponding 12-[5-arylfuran(thiophen, N-methylpyrrol)-2-yl]-7,8,9,10-tetradrobenzo[a]acridin-11(12H)-ones.

Discovery of new Gram-negative antivirulence drugs: Structure and properties of novel E. coli WaaC inhibitors

Heptosyltransferases such as WaaC represent promising and attractive targets for the discovery of new Gram-negative antibacterial drugs based on antivirulence mechanisms. We report herein our approach to the identification of the first micromolar inhibitors of WaaC and the preliminary SAR generated from this family of 2-aryl-5-methyl-4-(5-aryl-furan-2-yl-methylene)-2,4-dihydro-pyrazol-3-on es identified by virtual screening.

Inhibitors of HCV NS5B polymerase. Part 1: Evaluation of the southern region of (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid

A novel series of nonnucleoside HCV NS5B polymerase inhibitors were prepared from (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid, a high throughput screening lead. SAR studies combined with structure based drug design focusing on the southern heterobiaryl region of the template led to the synthesis of several potent and orally bioavailable lead compounds. X-ray crystallography studies were also performed to understand the interaction of these inhibitors with HCV NS5B polymerase.

Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties

In a previous report, we have provided evidence that novel anti-malarial compounds based on 2,5-diaminobenzophenone farnesyltransferase inhibitors might benefit from the presence of a polar moiety at the para position of the terminal phenyl of the arylfur